Cargando…

Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis

Background and Aims: Non-Hodgkin lymphoma (NHL) of the liver is a rare lymphoid malignancy, accounting for less than 1% of extranodal lymphomas. Methods: I conducted an analysis of the U.S Surveillance, Epidemiology, and End Results (SEER) database to evaluate the histological subtypes and the survi...

Descripción completa

Detalles Bibliográficos
Autor principal: El-Fattah, Mohamed Abd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472928/
https://www.ncbi.nlm.nih.gov/pubmed/28660145
http://dx.doi.org/10.14218/JCTH.2017.00015
_version_ 1783244208862134272
author El-Fattah, Mohamed Abd
author_facet El-Fattah, Mohamed Abd
author_sort El-Fattah, Mohamed Abd
collection PubMed
description Background and Aims: Non-Hodgkin lymphoma (NHL) of the liver is a rare lymphoid malignancy, accounting for less than 1% of extranodal lymphomas. Methods: I conducted an analysis of the U.S Surveillance, Epidemiology, and End Results (SEER) database to evaluate the histological subtypes and the survival outcomes of 785 cases with hepatic NHL between 1973 and 2012. Results: There were 785 of 312 459 cases with NHL had a first primary hepatic NHL (0.25%). Of the total 785 cases, the median age at diagnosis was 61 years (range 3–95 years) and male-female ratio of 1.7:1. The most common subtype was diffuse large B cell lymphoma (63.2%). In all patients, the median overall survival (OS) was 33 months (95%CI, 22–48 months). The 5-year OS rate for indolent B-cell NHLs was 62%, compared with 44% for an aggressive B-cell NHLs and 42% for T-cell NHLs. The median OS improved from 19 months in patients diagnosed in a period 1996–2000 to 60 months when diagnosed between 2006 and 2012 (p < .001). In a multivariable Cox regression analysis, the age ≥80 years (adjusted hazard ratio [aHR] 3.21, p < .001), male gender (aHR 1.26, p = .02), Black race (aHR, 1.70, p < .001), and T-cell NHL variants (aHR 1.73, p = .03) were unfavourable prognostic factors. Conclusion: NHL of the liver comprises about 0.3% of all NHLs and survival was improved in the recent calendar period.
format Online
Article
Text
id pubmed-5472928
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-54729282017-06-28 Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis El-Fattah, Mohamed Abd J Clin Transl Hepatol Original Article Background and Aims: Non-Hodgkin lymphoma (NHL) of the liver is a rare lymphoid malignancy, accounting for less than 1% of extranodal lymphomas. Methods: I conducted an analysis of the U.S Surveillance, Epidemiology, and End Results (SEER) database to evaluate the histological subtypes and the survival outcomes of 785 cases with hepatic NHL between 1973 and 2012. Results: There were 785 of 312 459 cases with NHL had a first primary hepatic NHL (0.25%). Of the total 785 cases, the median age at diagnosis was 61 years (range 3–95 years) and male-female ratio of 1.7:1. The most common subtype was diffuse large B cell lymphoma (63.2%). In all patients, the median overall survival (OS) was 33 months (95%CI, 22–48 months). The 5-year OS rate for indolent B-cell NHLs was 62%, compared with 44% for an aggressive B-cell NHLs and 42% for T-cell NHLs. The median OS improved from 19 months in patients diagnosed in a period 1996–2000 to 60 months when diagnosed between 2006 and 2012 (p < .001). In a multivariable Cox regression analysis, the age ≥80 years (adjusted hazard ratio [aHR] 3.21, p < .001), male gender (aHR 1.26, p = .02), Black race (aHR, 1.70, p < .001), and T-cell NHL variants (aHR 1.73, p = .03) were unfavourable prognostic factors. Conclusion: NHL of the liver comprises about 0.3% of all NHLs and survival was improved in the recent calendar period. XIA & HE Publishing Inc. 2017-05-14 2017-06-28 /pmc/articles/PMC5472928/ /pubmed/28660145 http://dx.doi.org/10.14218/JCTH.2017.00015 Text en © 2017 Authors. http://creativecommons.org/licenses/by-nc/4.0/ This article has been published under the terms of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. “This article has been published in Journal of Clinical and Translational Hepatology at DOI: 10.14218/JCTH.2017.00015 and can also be viewed on the Journal’s website at http://www.jcthnet.com”.
spellingShingle Original Article
El-Fattah, Mohamed Abd
Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis
title Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis
title_full Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis
title_fullStr Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis
title_full_unstemmed Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis
title_short Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis
title_sort non-hodgkin lymphoma of the liver: a us population-based analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472928/
https://www.ncbi.nlm.nih.gov/pubmed/28660145
http://dx.doi.org/10.14218/JCTH.2017.00015
work_keys_str_mv AT elfattahmohamedabd nonhodgkinlymphomaoftheliverauspopulationbasedanalysis